GO:0070975 FHA domain binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070975 (FHA domain binding) is a molecular function describing the binding of a protein or peptide to a forkhead-associated (FHA) domain, an approximately 80-100 residue phosphopeptide-recognition module folded into an 11-stranded beta sandwich.
• FHA domains preferentially recognize phosphothreonine (pThr) over phosphoserine, and this specificity is dictated by a conserved pocket that coordinates the phosphate and the threonine methyl group.
• FHA domain binding is central to DNA damage response signaling, where FHA-containing proteins such as the budding yeast Rad53 and human CHK2 kinases interact with phosphorylated adaptors to propagate checkpoint signals.
• Beyond DNA repair, FHA domain-mediated interactions regulate receptor kinase-associated protein phosphatase (KAPP) in Arabidopsis and other plant signaling pathways, demonstrating evolutionary conservation.
• FHA domains can also engage non-phosphorylated ligands and mediate protein-protein interactions beyond simple phosphopeptide recognition, expanding the functional repertoire of this module.
• Dysregulation of FHA domain-dependent interactions has been implicated in cancer, immunodeficiency, and developmental disorders, making these interactions attractive targets for mechanistic and therapeutic studies.
Description
The Gene Ontology molecular function term GO:0070975, FHA domain binding, describes the binding of a protein or peptide to a forkhead-associated (FHA) domain. The FHA domain is a compact phosphopeptide-recognition module of approximately 80-100 amino acid residues that folds into an 11-stranded beta sandwich and is found in many regulatory proteins across eukaryotes. This binding event is a fundamental mechanism for assembling phosphorylation-dependent signaling complexes, particularly in DNA damage responses, cell cycle checkpoints, and receptor kinase pathways. Researchers study FHA domain binding to understand how cells decode phosphothreonine signals into specific biological outcomes, and to identify vulnerabilities in diseases where these signaling circuits are rewired. The interaction is highly selective: FHA domains typically bind phosphothreonine-containing motifs with moderate affinity and high specificity, a property that enables precise temporal and spatial control of signaling. Because FHA domain binding is a molecular function rather than a single pathway, it intersects with diverse processes including DNA repair, transcriptional regulation, and plant innate immunity. This article synthesizes authoritative QuickGO annotation data and verified PubMed literature to provide a research-grade overview of GO:0070975, its structural basis, key genes, disease relevance, and experimental strategies for interrogation.
FHA domain binding At A Glance
| GO ID | GO:0070975 |
|---|---|
| GO term | FHA domain binding |
| Ontology | molecular_function |
| Synonym | Forkhead-associated domain binding |
| Definition | Binding to a FHA domain of a protein. The FHA domain is a phosphopeptide recognition domain found in many regulatory proteins, and consists of approximately 80-100 amino acid residues folded into an 11-stranded beta sandwich. |
| Major function | Mediates phosphorylation-dependent protein-protein interactions, particularly through phosphothreonine recognition, in DNA damage response, cell cycle checkpoints, and receptor signaling. |
| Structural fold | 11-stranded beta sandwich with a conserved phosphopeptide-binding pocket. |
| Ligand preference | Phosphothreonine-containing peptides; phosphoserine is generally disfavored. |
| Representative proteins | Rad53, CHK2, KAPP, and other FHA-containing regulatory proteins. |
What Is GO:0070975?
FHA domain binding (GO:0070975) is the molecular function of selectively interacting with a forkhead-associated (FHA) domain of a protein. The FHA domain is a phosphopeptide recognition domain found in many regulatory proteins and consists of approximately 80-100 amino acid residues folded into an 11-stranded beta sandwich. This binding typically involves a phosphorylated threonine residue on the ligand, which docks into a conserved pocket on the FHA domain, although non-phosphorylated interactions have also been reported.
Why Is FHA domain binding Important in Cell Biology?
FHA domain binding is a critical molecular function for translating phosphorylation signals into specific cellular responses. It enables the assembly of multiprotein complexes that sense and repair DNA damage, control cell cycle progression, and regulate receptor kinase signaling in plants and animals. Because FHA domain interactions are highly selective for phosphothreonine, they provide a paradigm for understanding how post-translational modifications encode information. Dysregulation of FHA domain binding can lead to genomic instability, cancer predisposition, and immune dysfunction, making it a focus for both basic and translational research.
• FHA domain binding is essential for DNA damage checkpoint signaling, where it mediates interactions between Rad53/CHK2 and phosphorylated adaptor proteins.
• It provides a mechanism for phosphothreonine-specific signal transduction, distinguishing pThr from pSer marks.
• FHA domain interactions are conserved across eukaryotes, from yeast to plants to humans.
• In plants, FHA domain binding regulates receptor kinase-associated protein phosphatase (KAPP) and innate immunity.
• FHA domains can also bind non-phosphorylated partners, expanding their regulatory roles beyond phosphopeptide recognition.
• Mutations affecting FHA domain binding are linked to cancer and developmental disorders.
• Understanding FHA domain binding informs the design of inhibitors that disrupt pathological protein-protein interactions.
• FHA domain binding is a model system for studying phosphopeptide recognition specificity and affinity.
• It contributes to the regulation of cell cycle checkpoints and genome maintenance.
• FHA domain binding is relevant to biotechnology applications, including engineered signaling proteins and biosensors.
Molecular Mechanism of FHA domain binding
Phosphothreonine recognition
In simple terms: The FHA domain acts like a lock that fits a specific phosphorylated key on another protein.
FHA domains contain a conserved binding pocket that coordinates the phosphate group of a phosphothreonine residue on the target protein. Structural studies show that the pocket includes conserved residues that hydrogen-bond with the phosphate and make van der Waals contacts with the threonine methyl group, conferring specificity for pThr over pSer. This binding is typically of moderate affinity, allowing reversible complex formation.
Structural basis of the beta sandwich fold
In simple terms: The FHA domain is built from a stable, sandwich-like arrangement of beta strands that positions the binding pocket.
The FHA domain folds into an 11-stranded beta sandwich, a compact and rigid structure that presents the phosphopeptide-binding surface. NMR and crystallographic studies have shown that ligand binding can globally rigidify the domain, reducing conformational flexibility and stabilizing the bound state. This structural rigidity is thought to facilitate high-specificity recognition.
Beyond phosphopeptide binding
In simple terms: FHA domains can sometimes bind proteins even without a phosphate group, adding versatility.
While FHA domains are best known for phosphothreonine recognition, emerging evidence indicates that they can also mediate interactions with non-phosphorylated ligands. These alternative binding modes may involve distinct surface patches and can regulate processes independently of phosphorylation. This expands the functional scope of FHA domain binding beyond classical DNA damage signaling.
Assembly of signaling complexes
In simple terms: FHA domain binding helps bring together multiple proteins into a working machine.
FHA domain interactions often serve as nucleation points for assembling larger signaling complexes. For example, in the DNA damage response, FHA domain-mediated binding of Rad53 to phosphorylated Rad9 scaffolds promotes checkpoint activation. Similarly, in plants, FHA domain-containing KAPP interacts with phosphorylated receptor kinases to modulate signaling output. These complexes amplify and propagate signals through cooperative interactions.
Regulation by phosphorylation and dephosphorylation
In simple terms: Adding or removing phosphate groups on the target protein controls whether the FHA domain can bind.
The interaction between an FHA domain and its ligand is dynamically regulated by kinases and phosphatases that add or remove the phosphothreonine mark. This reversible modification allows cells to switch signaling complexes on and off in response to stimuli such as DNA damage or pathogen attack. The specificity of FHA domains for pThr ensures that only appropriate signals trigger complex assembly.
Key Genes Involved in GO:0070975 FHA domain binding
The following genes and proteins are representative of FHA domain binding function, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RAD53 (yeast) | FHA domain-containing kinase that binds phosphorylated Rad9 to activate DNA damage checkpoint | Model for studying checkpoint signaling and FHA domain function |
| CHK2 (human) | FHA domain-containing kinase involved in DNA damage response and cell cycle arrest | Cancer susceptibility gene; target for FHA domain binding studies |
| KAPP (Arabidopsis) | FHA domain-containing phosphatase that interacts with phosphorylated receptor kinases | Plant signaling model for FHA domain binding |
| RAD9 (yeast) | Phosphorylated adaptor protein that binds Rad53 FHA domain | Scaffold for FHA domain interaction studies |
| MDC1 (human) | FHA domain-containing mediator of DNA damage response | Cancer and genome stability research |
| AGGF1 (human) | Angiogenic factor with FHA domain and GTPase domain; involved in TNFSF12/FN14 signaling | Retinal angiogenesis and vascular biology |
| RAD53 FHA1 domain | Isolated FHA domain used in biophysical and structural studies | Model for phosphopeptide binding specificity |
| RAD53 FHA2 domain | Second FHA domain in Rad53 with distinct ligand specificity | Comparative studies of FHA domain function |
| FHA2-Aktpep fusion | Engineered construct for detecting FHA domain binding | Biosensor development |
| NFluc-FHA2-Aktpep-CFluc | Split luciferase reporter for FHA domain binding | High-throughput screening of FHA domain interactions |
| Rad53 homologs | Conserved FHA domain kinases in fungi | Evolutionary studies of FHA domain binding |
| Plant receptor kinases | Phosphorylated kinases that recruit KAPP via FHA domain | Plant immunity and development |
| CHK2 FHA domain | Phosphopeptide-binding module critical for CHK2 activation | Structural and functional studies |
| MDC1 FHA domain | Binds phosphorylated H2AX to recruit DNA repair factors | DNA damage response research |
| FHA domain-containing proteins in Arabidopsis | Regulate receptor kinase-associated protein phosphatase activity | Plant signal transduction |
| AGGF1 FHA domain | Mediates protein interactions in angiogenesis | Vascular disease models |
| Rad53 FHA domain mutants | Used to dissect phosphopeptide binding specificity | Structure-function analysis |
How Is FHA domain binding Regulated?
FHA domain binding is regulated primarily by the phosphorylation state of the ligand. Kinases that phosphorylate threonine residues within specific motifs create docking sites for FHA domains, while phosphatases remove these marks to terminate interactions. In the DNA damage response, checkpoint kinases such as ATM/ATR phosphorylate adaptor proteins like Rad9 and MDC1, which then recruit FHA domain-containing effectors such as Rad53 and CHK2. Additionally, the intrinsic affinity and specificity of the FHA domain itself can be modulated by post-translational modifications or by interactions with other domains. In plants, receptor kinase activation leads to phosphorylation events that recruit KAPP via its FHA domain, providing a feedback mechanism to attenuate signaling.
FHA domain binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CHK2 | Cancer predisposition, DNA damage checkpoint defects | Knockout or point-mutation cell lines; xenograft models |
| MDC1 | Genome instability, cancer | Knockout cells; CRISPR knock-in of phospho-mutant |
| AGGF1 | Retinal angiogenesis, vascular disorders | Endothelial cell overexpression; knockout zebrafish |
| KAPP | Plant immunity and development | Arabidopsis knockout and point-mutation lines |
| RAD53 | DNA damage response (yeast model) | Yeast knockout and FHA domain mutants |
FHA domain binding in cancer
FHA domain-containing proteins such as CHK2 and MDC1 are critical for DNA damage checkpoints and genome maintenance. Mutations that impair FHA domain binding can lead to defective checkpoint responses, genomic instability, and increased cancer susceptibility. For example, CHK2 mutations affecting its FHA domain have been identified in cancer-prone families, highlighting the importance of this interaction for tumor suppression.
FHA domain binding in vascular and developmental disorders
AGGF1, a protein with an FHA domain, promotes retinal angiogenesis by coordinating TNFSF12/FN14 signaling. Dysregulation of AGGF1-mediated FHA domain interactions may contribute to vascular pathologies, making it a potential target for anti-angiogenic therapies.
FHA domain binding in plant immunity and disease resistance
In Arabidopsis, the FHA domain-containing phosphatase KAPP interacts with phosphorylated receptor kinases to modulate immune signaling. Disruption of FHA domain binding can alter disease resistance, providing insights into plant-pathogen interactions and potential agricultural applications.
From FHA domain binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FHA domain binding impair DNA damage checkpoint? | Knockout of FHA domain-containing gene (e.g., CHK2) in human cell lines |
| Which phosphothreonine residue is critical for FHA domain interaction? | Point mutation of predicted phospho-acceptor site in ligand |
| Can a disease-associated mutation be rescued by wild-type FHA domain? | Knock-in of wild-type or mutant FHA domain into endogenous locus |
| Where does FHA domain binding occur in live cells? | Tagged knock-in of FHA domain protein with fluorescent tag |
| Does overexpression of FHA domain ligand alter signaling? | Overexpression of ligand or FHA domain protein in cell lines |
| What is the affinity and specificity of FHA domain binding? | Recombinant FHA domain protein for in vitro binding assays |
How to Study the FHA domain binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Isothermal titration calorimetry (ITC) | Binding affinity and stoichiometry | Quantify FHA domain-phosphopeptide interaction |
| Surface plasmon resonance (SPR) | Real-time binding kinetics | Measure on/off rates for FHA domain ligands |
| NMR spectroscopy | Structural changes and binding interface | Map FHA domain residues involved in phosphopeptide binding |
| X-ray crystallography | Three-dimensional structure | Determine atomic details of FHA domain-ligand complexes |
| Co-immunoprecipitation | Protein-protein interactions in cells | Detect endogenous FHA domain complexes |
| Split-luciferase complementation | FHA domain binding in live cells | High-throughput screening of interaction modulators |
| Phosphoproteomics | Global phosphorylation status | Identify ligands and signaling networks for FHA domains |
| CRISPR knockout screening | Gene function in FHA domain binding | Discover regulators of FHA domain-dependent pathways |
Biophysical binding assays
Isothermal titration calorimetry (ITC), surface plasmon resonance (SPR), and nuclear magnetic resonance (NMR) spectroscopy are used to measure the affinity and specificity of FHA domain binding to phosphopeptides. These methods provide quantitative parameters such as dissociation constants (Kd) and reveal structural changes upon binding.
Structural biology
X-ray crystallography and NMR spectroscopy have solved structures of FHA domains in complex with phosphopeptides, revealing the molecular basis of pThr recognition and the beta sandwich fold. These studies guide mutational analysis and inhibitor design.
Cell-based interaction assays
Co-immunoprecipitation, pull-down assays with recombinant FHA domains, and split-luciferase complementation (e.g., NFluc-FHA2-Aktpep-CFluc) are used to detect FHA domain binding in cell lysates or live cells. These methods allow mapping of interaction domains and identification of novel partners.
Functional genomics and screening
CRISPR knockout libraries, RNA interference, and phosphoproteomics can identify genes and phosphorylation events that regulate FHA domain binding. High-throughput screens using split-luciferase reporters enable discovery of modulators of FHA domain interactions.
How CRISPR Can Be Used to Study GO:0070975 FHA domain binding
Knockout
CRISPR knockout of genes encoding FHA domain-containing proteins or their phosphorylated ligands can abolish specific binding interactions, revealing their role in DNA damage response, angiogenesis, or plant immunity. For example, knocking out CHK2 or MDC1 impairs checkpoint signaling and sensitizes cells to DNA-damaging agents.
Point Mutation
Introducing point mutations into the FHA domain or the phospho-acceptor site of the ligand via CRISPR base editing or homology-directed repair allows precise dissection of binding determinants. Mutating the conserved pThr-binding pocket residues in an FHA domain can eliminate binding without affecting protein stability.
Knock-in
Knock-in of tagged or mutant FHA domain proteins (e.g., fluorescent tags or epitope tags) enables visualization and biochemical isolation of FHA domain complexes under endogenous regulation. This approach is valuable for studying dynamic interactions in live cells.
Overexpression
Overexpression of FHA domain-containing proteins or their ligands can amplify signaling and facilitate detection of weak or transient interactions. It is also used to test gain-of-function effects in disease models, such as AGGF1 in angiogenesis.
How EDITGENE Supports FHA domain binding Research
Researchers studying FHA domain binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. This requires precise genetic manipulation, from complete knockout to subtle point mutations that disrupt only the binding interface. EDITGENE provides a comprehensive suite of CRISPR-based services tailored to these needs, enabling rigorous mechanistic studies of FHA domain interactions.
Contact EDITGENE today to design your custom CRISPR model for FHA domain binding research.
Frequently Asked Questions About FHA domain binding
What is FHA domain binding?
FHA domain binding (GO:0070975) is the molecular function of binding to a forkhead-associated (FHA) domain, a phosphopeptide-recognition module of about 80-100 amino acids that folds into an 11-stranded beta sandwich.
What genes are involved in FHA domain binding?
Key genes include RAD53 and CHK2 kinases, MDC1, AGGF1, and plant KAPP, all of which contain FHA domains or serve as ligands.
What does the FHA domain recognize?
FHA domains preferentially recognize phosphothreonine-containing peptides, with high specificity over phosphoserine.
How is FHA domain binding regulated?
It is regulated by kinases and phosphatases that add or remove the phosphothreonine mark on the ligand, controlling complex assembly.
What diseases are associated with FHA domain binding?
Defects in FHA domain interactions are linked to cancer, genomic instability, vascular disorders, and plant immunity defects.
What methods are used to study FHA domain binding?
Common methods include ITC, SPR, NMR, X-ray crystallography, co-immunoprecipitation, split-luciferase assays, and CRISPR screens.
Can FHA domains bind non-phosphorylated proteins?
Yes, emerging evidence shows that FHA domains can also engage non-phosphorylated ligands, expanding their functional roles.
What is the structure of the FHA domain?
The FHA domain is an 11-stranded beta sandwich with a conserved phosphopeptide-binding pocket.
How can CRISPR help study FHA domain binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of FHA domain interactions in cells and organisms.
Is FHA domain binding conserved across species?
Yes, FHA domains are found in eukaryotes from yeast to plants to humans, and their binding function is conserved.
Conclusion
FHA domain binding (GO:0070975) is a fundamental molecular function that decodes phosphothreonine signals into specific cellular responses, with critical roles in DNA damage checkpoints, angiogenesis, and plant immunity. Its structural basis and regulatory mechanisms are well studied, and its dysfunction is linked to cancer and other diseases. Continued research using CRISPR-based models and advanced biophysical methods will further illuminate how FHA domain interactions are wired and how they can be targeted therapeutically.
References
- 1. Durocher D et al.. 2002. The FHA domain.. FEBS Lett 513(1):58-66 PMID: 11911881
- 2. Cheng Y et al.. 2025. Endothelial AGGF1 promotes retinal angiogenesis by coordinating TNFSF12/FN14 signalling.. Nat Commun 16(1):1332 PMID: 39905000
- 3. Huang M et al.. 2000. The FHA domain, a phosphoamino acid binding domain involved in the DNA damage response pathway.. Cold Spring Harb Symp Quant Biol 65:413-21 PMID: 12760057
- 4. Zhang H. 2004. NFluc-FHA2-Aktpep-CFluc.. PMID: 20641681
- 5. Almawi AW et al.. 2017. FHA domains: Phosphopeptide binding and beyond.. Prog Biophys Mol Biol 127:105-110 PMID: 27939759
- 6. Li J et al.. 2000. The FHA domain mediates phosphoprotein interactions.. J Cell Sci 113 Pt 23:4143-9 PMID: 11069759
- 7. Coquelle N et al.. 2010. FHA domain pThr binding specificity: it's all about me.. Structure 18(12):1549-50 PMID: 21134632
- 8. Ding Z et al.. 2005. PhosphoThr peptide binding globally rigidifies much of the FHA domain from Arabidopsis receptor kinase-associated protein phosphatase.. Biochemistry 44(30):10119-34 PMID: 16042389
